https://mindmedicinelaw.com/briefing/fda-s-new-guidance-on-psychedelic-trials-implications-and-risks-20260715-22403The Psychedelic Journalen2026-07-15T15:04:28.184932+00:00FDA's New Guidance on Psychedelic Trials: Implications and RisksFDA guidance, psychedelic trials, clinical trial design, safety considerations, mental health treatment, psychedelic research, regulatory framework, drug development, trial ethics, therapy approvalhttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-and-spiritual-potential-shurooms-analysis-20260714-22460The Psychedelic Journalen2026-07-15T22:05:47.068895+00:00Psilocybin's Therapeutic and Spiritual Potential: Shurooms Analysispsilocybin, psychedelic therapy, neuroplasticity, mental health, spiritual practices, entheogens, Ajarn Shaman Shu, treatment-resistant depression, anxiety, PTSDhttps://mindmedicinelaw.com/briefing/psilocybin-in-palliative-care-promising-pilot-study-results-20260714-22461The Psychedelic Journalen2026-07-15T22:05:02.508093+00:00Psilocybin in Palliative Care: Promising Pilot Study Resultspsilocybin-assisted therapy, palliative care, demoralization, chronic pain, cancer patients, psychedelic research, clinical trials, mental health, spiritual health, multidisciplinary carehttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-licensing-fees-new-rulemaking-by-oha-20260714-22407The Psychedelic Journalen2026-07-15T15:05:13.450876+00:00Oregon's Psilocybin Licensing Fees: New Rulemaking by OHAOregon Health Authority, psilocybin licensing fees, psilocybin regulation, small business impact, therapeutic psilocybin, psilocybin market dynamics, regulatory challenges, psilocybin access, policy implications, psilocybin program sustainabilityhttps://mindmedicinelaw.com/briefing/hhs-and-va-accelerate-psychedelic-treatments-for-veterans-20260714-22406The Psychedelic Journalen2026-07-15T15:04:55.419553+00:00HHS and VA Accelerate Psychedelic Treatments for VeteransHHS, VA, psychedelic treatments, veterans, mental health, federal policy, clinical trials, MDMA, psilocybin, healthcare reformhttps://mindmedicinelaw.com/briefing/compass-pathways-phase-3-psilocybin-trials-and-fda-guidance-20260714-22402The Psychedelic Journalen2026-07-15T15:04:46.767977+00:00Compass Pathways' Phase 3 Psilocybin Trials and FDA Guidancepsilocybin, Compass Pathways, Phase 3 trials, FDA guidance, treatment-resistant depression, psychedelic therapies, regulatory challenges, market uncertainties, clinical research, legal statushttps://mindmedicinelaw.com/briefing/fda-breakthrough-therapy-designation-for-psychedelics-implications-20260714-22404The Psychedelic Journalen2026-07-15T15:04:38.541457+00:00FDA Breakthrough Therapy Designation for Psychedelics: ImplicationsFDA Breakthrough Therapy Designation, psychedelic research, drug development, clinical trials, regulatory approval, unmet medical needs, psychedelic therapies, market dynamics, policy implications, safety and efficacyhttps://mindmedicinelaw.com/briefing/dmt-harmine-formulation-reduces-negative-emotions-in-trials-20260714-21974The Psychedelic Journalen2026-07-14T15:07:09.599688+00:00DMT-Harmine Formulation Reduces Negative Emotions in TrialsDMT, harmine, negative emotions, psychedelic research, clinical trials, ayahuasca, self-referential processing, psychiatric disorders, emotional modulation, mental health treatmenthttps://mindmedicinelaw.com/briefing/fda-hearing-on-psychedelic-therapeutics-implications-for-policy-20260714-21889The Psychedelic Journalen2026-07-14T15:07:01.030844+00:00FDA Hearing on Psychedelic Therapeutics: Implications for PolicyFDA hearing, psychedelic therapeutics, regulatory changes, clinical trials, mental health treatment, therapeutic use of psychedelics, policy implications, psychedelic drugs, public health, drug schedulinghttps://mindmedicinelaw.com/briefing/federal-rfi-on-safe-psychedelic-therapy-models-in-clinics-20260714-21898The Psychedelic Journalen2026-07-14T15:06:51.886951+00:00Federal RFI on Safe Psychedelic Therapy Models in Clinicspsychedelic therapies, FDA approval, mental health treatment, clinical settings, stakeholder feedback, Executive Order 14401, ambulatory clinics, training models, patient safety, regulatory frameworkshttps://mindmedicinelaw.com/briefing/fda-finalizes-guidance-on-psychedelic-clinical-trials-20260714-21897The Psychedelic Journalen2026-07-14T15:06:42.505224+00:00FDA Finalizes Guidance on Psychedelic Clinical TrialsFDA guidance, psychedelic clinical trials, drug development, psychedelic therapies, regulatory framework, clinical research, mental health treatment, safety monitoring, therapeutic potential, psychiatric disordershttps://mindmedicinelaw.com/briefing/systems-based-psychiatry-insights-from-psychedelic-research-20260713-22465The Psychedelic Journalen2026-07-15T22:05:30.304495+00:00Systems-Based Psychiatry: Insights from Psychedelic Researchpsychedelic research, systems-based psychiatry, psychiatric disorders, therapeutic reorganization, mental health care, clinical implementationhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-trials-reporting-practices-and-gaps-20260713-22466The Psychedelic Journalen2026-07-15T22:05:23.605307+00:00Psilocybin Therapy Trials: Reporting Practices and Gapspsilocybin-assisted therapy, depression trials, reporting practices, clinical trial standardization, blinding success, therapist fidelity, psychedelic research, treatment-resistant depression, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/sex-differences-in-psychedelic-responses-implications-for-trials-20260713-22464The Psychedelic Journalen2026-07-15T22:05:12.403433+00:00Sex Differences in Psychedelic Responses: Implications for Trialspsychedelic research, sex differences, clinical trials, subjective effects, dosing strategies, safety protocols, pharmacodynamicshttps://mindmedicinelaw.com/briefing/n-nitroso-ketamine-formation-manufacturing-implications-20260713-22400The Psychedelic Journalen2026-07-15T15:05:03.804494+00:00N-nitroso-ketamine Formation: Manufacturing ImplicationsN-nitroso-ketamine, ketamine manufacturing, pharmaceutical safety, process design, solvent selection, activated carbon, regulatory standards, clinical use, market availability, manufacturing riskshttps://mindmedicinelaw.com/briefing/generative-art-in-depression-therapy-ethics-and-efficacy-20260713-21975The Psychedelic Journalen2026-07-14T15:07:27.232567+00:00Generative Art in Depression Therapy: Ethics and Efficacygenerative art, depression therapy, digital technology, psychological intervention, ethical challenges, interactive art, emotional mapping, neuro-regulation, sensory overload, virtual escapismhttps://mindmedicinelaw.com/briefing/immune-inflammatory-mechanisms-in-depression-and-metabolic-syndrome-20260713-21984The Psychedelic Journalen2026-07-14T15:07:17.986600+00:00Immune-Inflammatory Mechanisms in Depression and Metabolic Syndromeimmune-inflammatory mechanisms, major depressive disorder, metabolic syndrome, precision therapies, multi-omics studies, chronic low-grade inflammation, immune signaling pathways, personalized management, anti-inflammatory interventions, translational researchhttps://mindmedicinelaw.com/briefing/glutamatergic-augmentation-in-adolescent-anxiety-depression-20260711-21985The Psychedelic Journalen2026-07-14T22:05:42.819707+00:00Glutamatergic Augmentation in Adolescent Anxiety-Depressionglutamatergic modulation, adolescent anxiety, NMDA-AMPA modulation, obsessive symptoms, clinical trials, polypharmacy, mental health treatment, neuroscience, public health, psychedelic researchhttps://mindmedicinelaw.com/briefing/dmt-s-proliferative-effects-on-neural-stem-cells-implications-20260709-22395The Psychedelic Journalen2026-07-15T22:05:38.169440+00:00DMT's Proliferative Effects on Neural Stem Cells: ImplicationsDMT, neural stem cells, neurogenesis, psychedelic research, neurodegenerative diseases, serotonin receptors, clinical trials, Schedule I substance, brain plasticity, therapeutic applicationshttps://mindmedicinelaw.com/briefing/spontaneous-thought-dynamics-and-affectivity-new-insights-20260709-21134The Psychedelic Journalen2026-07-14T22:06:00.571530+00:00Spontaneous Thought Dynamics and Affectivity: New Insightsspontaneous thought dynamics, Density Map-Based Predictive Modeling, affectivity, salivary C-reactive protein, mental health diagnostics, psychedelic-assisted therapy, thought transition dynamics, physiological markers, Free Association Semantic Task, valence–self-relevance–time spacehttps://mindmedicinelaw.com/briefing/hemodynamic-signals-role-in-calcium-imaging-interpretation-20260709-21135The Psychedelic Journalen2026-07-14T22:05:51.252459+00:00Hemodynamic Signals' Role in Calcium Imaging Interpretationhemodynamic signals, calcium imaging, cortical dynamics, vascular remodeling, glioblastoma, neuroscience research, functional connectivity, network modularity, brain imaging, data interpretationhttps://mindmedicinelaw.com/briefing/tcm-s-role-in-treating-major-depressive-disorder-a-review-20260708-21982The Psychedelic Journalen2026-07-14T22:06:08.260049+00:00TCM's Role in Treating Major Depressive Disorder: A Reviewtraditional chinese medicine, major depressive disorder, network pharmacology, multi-omics, treatment-resistant depression, holistic treatment, bioactive compounds, clinical trials, neuroplasticity, adjunctive treatmenthttps://mindmedicinelaw.com/briefing/ibogaine-psychedelics-for-pain-pharmacy-practice-changes-20260708-22210The Psychedelic Journalen2026-07-14T22:05:33.293327+00:00Ibogaine & Psychedelics for Pain: Pharmacy Practice Changespsychedelics, ibogaine, pain management, pharmacy practice, clinical trials, neuroscience, public health, psychedelic research, pharmaceutical policy, pain medicationshttps://mindmedicinelaw.com/briefing/hydrogen-bonds-and-bbb-permeability-in-cns-drug-design-20260705-21323The Psychedelic Journalen2026-07-14T22:06:16.000098+00:00Hydrogen Bonds and BBB Permeability in CNS Drug Designblood-brain barrier, hydrogen bond donors, intramolecular hydrogen bonding, CNS drug design, psychedelic compounds, brain permeability, drug delivery, pharmacological efficacy